Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Phase 1/2 Recruiting
52 enrolled
STOP VEN
Phase 2 Recruiting
50 enrolled
A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
12 enrolled
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Phase 1 Recruiting
30 enrolled
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Phase 1/2 Recruiting
96 enrolled
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
Phase 1 Recruiting
32 enrolled
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Phase 1/2 Recruiting
40 enrolled
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Phase 2 Recruiting
45 enrolled
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Phase 2 Recruiting
50 enrolled
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
Phase 1 Recruiting
43 enrolled
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
Phase 2 Recruiting
28 enrolled
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Phase 1 Recruiting
24 enrolled
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
Phase 2 Recruiting
27 enrolled
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
Phase 2 Recruiting
56 enrolled
REMAIN1
Phase 4 Recruiting
12 enrolled
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Phase 3 Recruiting
240 enrolled
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Phase 2 Recruiting
37 enrolled
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
Phase 2 Recruiting
30 enrolled
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
Phase 1 Recruiting
24 enrolled
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2 Recruiting
63 enrolled
PlaTform
Phase 1/2 Recruiting
49 enrolled
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Phase 1/2 Recruiting
31 enrolled
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
Phase 2/3 Recruiting
40 enrolled
TAGALONG
Phase 2 Recruiting
53 enrolled
BRE-04
Phase 2 Recruiting
40 enrolled
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
Phase 2 Recruiting
50 enrolled
IMAGINE
Phase 1 Recruiting
36 enrolled
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Phase 1 Recruiting
18 enrolled
Cladribine Venetoclax in Monocytic AML
Phase 2 Recruiting
20 enrolled
Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
Phase 2 Recruiting
40 enrolled
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Phase 1/2 Recruiting
97 enrolled
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
Phase 3 Recruiting
170 enrolled
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
Phase 2 Recruiting
92 enrolled
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
Phase NA Recruiting
43 enrolled
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Phase 2 Recruiting
240 enrolled
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Phase 2 Recruiting
172 enrolled
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1 Recruiting
72 enrolled
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
Phase 1/2 Recruiting
20 enrolled
Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI
Phase 1/2 Recruiting
10 enrolled
VERDI
Phase 2 Recruiting
29 enrolled
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
Phase 2 Recruiting
30 enrolled
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
Phase 2 Recruiting
27 enrolled
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML
Phase 2 Recruiting
40 enrolled
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
51 enrolled
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Phase 2 Recruiting
40 enrolled
Pacritinib in CMML
Phase 1/2 Recruiting
26 enrolled
MRD-positive AML Clinical Study
Phase NA Recruiting
120 enrolled
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
Phase 1 Recruiting
24 enrolled
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Phase 2 Recruiting
50 enrolled
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
Phase 2 Recruiting
32 enrolled